ABX Outcome Study: SSI Reduction Results | Aerobiotix

ABX Outcome Study: SSI Reduction Results

Study Location
Confidential Community Hospital
Atlanta, Georgia USA


Elevated airborne pathogen levels in healthcare settings are a significant, yet under-appreciated cause of hospital acquired infections (HAI) and surgical site infections (SSI) ², ³. In orthopedic surgery, strong correlation exists between the air contamination, the joint sepsis rate and the number of bacteria isolated from wound washout samples ³. In the United States, no minimal standard exists for the number of airborne bacteria, viruses, or fungi in the healthcare settings, including critical areas of surgery suites, immunocompromised patient areas, or intensive care units. Global increase in antibiotic resistant bacterial strains and rise in MRSE occurrence further exaggerate the morbidity and mortality of HAIs and SSIs. Consequently, improving environmental controls in the OR by reducing airborne pathogen burden should take precedence over the development of new prophylactic antibiotic programs. ⁴⁻⁷
The ABX in-room germicidal C-UVC filtration/recirculation unit utilizes a hybrid of biological and physical filtration systems to remove bacteria, fungi and viruses from the air. Its key biocidal technology is a solidstate germicidal irradiation system which provides simultaneous physical filtration and irradiation of highvolume air flow. The system utilizes C-band ultraviolet light (UV-C) at a 254 nm wavelength diffused into a solid media which is gas and radiation permeable. While organisms are slowed or trapped in the solid media, they are inactivated by the internal UV-C dosage (Figure 1).
The ABX technology has previously demonstrated statistically significant reductions in airborne particles
and bacterial colony-forming units when deployed in active ORs.


The implementation of ABX technology in active orthopedic OR performing spinal and joint replacement surgical procedures reduced SSI incidence by 66% (Figure 2).

Figure 2. Decreased incidence of surgical site infections following the implementation of ABX technology in active orthopaedic ORs. CENTER – total number of cases observed; PERIPHERY – number of surgical site infections. The 66% decrease in SSI rate over the 5-month ABX technology implementation period.

Reach Us

444 Alexandersville Rd
Miamisburg, Ohio 45342

+1 888 978 7087

Reach Us

350 Fame Road
West Carrollton, Ohio 45449 USA

+1 888 978 7087



Sr. Vice President of Global Sales and Marketing

Jason leads our global sales team and brings over 18 years of Medical Device experience to Aerobiotix. Jason has led top performing National and Regional Sales teams, selling disruptive technology in the Cardiovascular space with Getinge, Surgical Robotics at Hansen Medical and most recently in the Biologics space with Axogen. Jason received his Bachelor of Science Degree from the University of Indianapolis.



Vice President of Global Marketing

Melissa Gietzen, MBA is a highly skilled strategic marketing professional with over 20 years’ experience in the healthcare industry. She has significant expertise in strategic planning, capital budgeting, service improvement projects, and creating strong successful brands in the orthopedic, cardiac & ophthalmology markets. Melissa holds a undergraduate degree in Management and Organization Development and a masters degree in Business Administration.



President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.

GREGORY CARROLL PH.D. Director Scientific Affairs


Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.

TONY EMBREE Chief Commercial Officer


Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.

COURTNEY ADAMS, Ph.D. VP of Clinical and Medical Affairs


VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.

ANTHONY DEFALCO Vice President of Engineering


Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.

NATHAN UTZ Vice President of Client Services


Vice President of Strategic Accounts

Nathan brings a high level of commitment to servicing and building client relations. Nathan has previously held leadership roles in the medical device industry.

MICHAEL SCHMITZ Chief Financial Officer


Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.